R. Caspi et al. found that rolipram, the first selective PDE4 inhibitor, had a protective effect in an EAU model (30), and Zai-Long Chi et al. found that rolipram could inhibit the pathogenesis of LPS-induced uveitis (31). This evidence concerns the gene PDE4A and uveitis.